CN Patent

CN103705517A — Src激酶抑制剂对溶骨性病变的抑制

Assigned to University of Texas at Austin · Expires 2014-04-09 · 12y expired

What this patent protects

本发明总地包括治疗骨再吸收疾病或与病理情况有关的骨再吸收的方法和组合物，其中所述疾病或情况包括但不限于，骨质疏松症、关节炎、类风湿性关节炎、癌向骨的转移、骨癌、高钙血症、具有矫形外科植入物的溶骨性病变、佩吉特病、和与甲状旁腺功能亢进有关的骨丢失。代表性的癌症包括但不限于，乳腺癌、前列腺癌、结肠癌、子宫内膜癌、多发性骨髓瘤、肾细胞癌、头和颈癌及宫颈癌。关节炎性病症包括但不限于，佐剂-、胶原-、细菌-和抗原-诱发的关节炎，特别是类风湿性关节炎。

USPTO Abstract

本发明总地包括治疗骨再吸收疾病或与病理情况有关的骨再吸收的方法和组合物，其中所述疾病或情况包括但不限于，骨质疏松症、关节炎、类风湿性关节炎、癌向骨的转移、骨癌、高钙血症、具有矫形外科植入物的溶骨性病变、佩吉特病、和与甲状旁腺功能亢进有关的骨丢失。代表性的癌症包括但不限于，乳腺癌、前列腺癌、结肠癌、子宫内膜癌、多发性骨髓瘤、肾细胞癌、头和颈癌及宫颈癌。关节炎性病症包括但不限于，佐剂-、胶原-、细菌-和抗原-诱发的关节炎，特别是类风湿性关节炎。

Drugs covered by this patent

bosutinib-monohydrate (BOSUTINIB MONOHYDRATE)

Patent Metadata

Patent number: CN103705517A
Jurisdiction: CN
Classification: —
Expires: 2014-04-09
Drug substance claim: No
Drug product claim: No
Assignee: University of Texas at Austin
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.